Vaccines to Prevent High-Grade Glioma

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

This video examines current research on the use of vaccines in low-grade glioma for the prevention of high-grade disease.

In this video, Hideho Okada, MD, PhD, of the University of California, San Francisco, discusses current research on the use of vaccines in low-grade glioma for the prevention of high-grade disease.

Okada gave a presentation on this topic at the 2017 American Association for Cancer Researcher (AACR) Annual Meeting, held April 1–5 in Washington, DC.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Related Content
The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

The safety profile of iopofosine I 131 in the phase 1b CLOVER-2 trial appears consistent with prior reports of the agent.

Iopofosine I 131 Shows Preliminary Survival Benefit in Pediatric R/R Glioma

Russ Conroy
June 11th 2025
Article

The safety profile of iopofosine I 131 in the phase 1b CLOVER-2 trial appears consistent with prior reports of the agent.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Forming Connections and Making a Difference in the Brain Cancer Field

Yoshie Umemura, MD
October 7th 2024
Podcast

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

FDA Grants RMAT Designation to CAR T Therapy for Incurable Pediatric Glioma

FDA Grants RMAT Designation to CAR T Therapy for Incurable Pediatric Glioma

Tim Cortese
May 16th 2025
Article

The B7-H3 CAR T-cell therapy showed positive survival results for younger patients with diffuse intrinsic pontine glioma in a phase 1 trial.

Maximizing Safe Resection in High-Grade Gliomas

Maximizing Safe Resection in High-Grade Gliomas

Ariana Pelosci
May 13th 2025
Article

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for newly diagnosed high-grade gliomas.